Drug updated on 6/26/2024
Dosage Form | Tablet (oral; linagliptin/ metformin; 2.5 mg /500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg) |
Drug Class | Dipeptidyl peptidase-4 inhibitors and biguanides |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Linagliptin and metformin hydrochloride (Jentadueto) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- The information comes from a single study, a randomized controlled trial.
- In the study, Jentadueto was compared with metformin alone. Both were combined with lifestyle changes in patients who have impaired glucose tolerance plus two risk factors for type 2 diabetes.
- Compared to using only metformin, the combination of linagliptin and metformin showed superior effectiveness in enhancing glucose metabolism, improving pancreatic β-cell function, reducing progression from prediabetes to type 2 diabetes, and increasing chances of achieving normoglycemia.
- No major side effects were observed during the study for either group, indicating that both treatment regimens are well tolerated by this specific population subgroup.
- This suggests that Jentadueto might be particularly beneficial for preventing progression to type 2 diabetes among individuals characterized by impaired glucose tolerance along with at least two other risk factors when used alongside lifestyle modifications.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information. | 2023 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. | 144Subjects F: 61% M: 39% | 2020 | Metabolism |
Sex Distribution:
F:61%
M:39%
144Subjects
Year:
2020
Source:Metabolism
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Management of individuals with diabetes at high risk for hypoglycemia: an endocrine society clinical practice guideline. | 2023 | The Journal of Clinical Endocrinology and Metabolism |
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. | 2022 | AACE Endocrine Practice |
Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. | 2020 | Canadian Journal of Diabetes |